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Small-cell carcinoma of the liver is a rare neoplasm, and no standard treatment for it has yet been established. A 72-year-old
man with an extensive disease stage of small-cell carcinoma of the liver was treated with systemic chemotherapy consisting of
cisplatin and etoposide (PE) followed by irinotecan. Although the masses were markedly decreased once after the sixth course
of PE, amrubicin monotherapy as third-line chemotherapy was started because the hepatic masses had increased again. The
administration of amrubicin was repeated in 8 courses with regression of the disease, resulting in a 26-month survival since the
ﬁrst-line chemotherapy was started. This is the ﬁrst case report of a refractory EPSCC successfully treated with amrubicin.
Copyright © 2009 Taichi Isobe et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Extrapulmonary small-cell carcinomas (EPSCCs) are found
in 2.5% to 4.0% of all small-cell carcinoma cases [1–3].
The common primary sites of EPSCCs are the salivary
gland, esophagus, stomach, pancreas, colon, and cervix [4].
The prognosis for patients with an advanced small-cell
carcinoma is poor, because of the aggressive phenotype and
the high frequency of metastasis. A standard treatment for
EPSCCs has not yet been established. Some cases have been
treated with a chemotherapeutic regimen for small-cell lung
carcinoma (SCLC), such as cisplatin (CDDP) plus etoposide
or CDDP plus irinotecan [1–4]. Recently, amrubicin, which
isatotallysynthetic9-aminoanthracyclineandapotentDNA
topoisomerase II inhibitor, has been demonstrated to be
eﬀectiveforpreviouslytreatedSCLCs[5,6].Wehereinreport
a patient with advanced small-cell carcinoma of the liver,
whowassuccessfullytreatedwithamrubicinmonotherapyas
third-line chemotherapy following cisplatin, etoposide, and
irinotecan, thus resulting in a long-term survival.
2.CaseReport
A72-year-oldmanwasreferredtousinMay2005,forfurther
examination of a gastric polyp. On physical examination,
his heart rate was 60/min and his blood pressure was
132/78mmHg. The abdominal examination was normal.
According to the Eastern Cooperative Oncology Group
(ECOG) criteria, the patient showed a performance status
of 0. The results of the routine laboratory tests were as
follows: total bilirubin, 0.6mg/dL; AST, 16 IU/L; ALT, 13
IU/L; hepatitis B viral surface antigen and hepatitis C viral
antibodywerenegative.Theserumlevelofα-Fetoproteinwas
normal. The serum levels of neuron-speciﬁc enolase (NSE),
gastrin-releasing peptide precursor (ProGRP), and carci-
noembryonic antigen (CEA) were elevated at 13.3ng/mL2 Case Reports in Medicine
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Figure 1: Abdominal computed tomography. Computed tomography revealed longest diameter 40mm-sized hepatic mass in the posterior
inferior segment of the liver (a) and small nodules scattered throughout both hepatic lobes (b). After 6 courses administration of amrubicin
as a third-line chemotherapy, the mass decreased (c).
(normal range; ∼10ng/mL), 408.0pg/mL (normal range;
∼46.0pg/mL), and 74.8ng/mL (normal range; ∼3.2ng/mL),
respectively. A chest radiograph showed clear lung ﬁelds. An
ultrasonographic examination revealed a hypoechoic mass
in the posterior inferior segment of the liver. Computed
tomography (CT) scans of the abdomen revealed that the
hepatic mass of the longest diameter (40mm) in size was
seen in the posterior inferior segment of the liver and that
small nodules were scattered throughout both of the hepatic
lobes (Figures 1(a) and 1(b)). A needle biopsy specimen
obtained from the hepatic mass demonstrated some nests
of atypical cells having large hyperchromatic nuclei and
scanty cytoplasm. Immunohistochemically, the atypical cells
were positive for cytokeratin (AE1/AE3 and CAM5.2) and
neuroendocrine markers (N-CAM and NSE), but negative
for a lymphocytic marker (LCA), which was consistent with
the features of a small-cell carcinoma (Figure 2). Addition-
ally, CK-19, CK-20, and hepatocyte speciﬁc antigen were
negative. Esophago-gastroduodenoscopy (EGD) revealed a
type IIc gastric cancer in the posterior wall of the lower
body of the stomach. A chest X-ray, CT scan of the chest,
bronchoscopy, and cytological examination of the sputum
showed no evidence of primary lung cancer. CT scans of the
brain and a scintigram of the bone revealed no metastatic
lesions. The ﬁnal diagnosis was an extensive disease stage
of small-cell carcinoma of the liver, and an early gastric
cancer.
The patient was initially treated with systemic chem-
otherapy consisting of both CDDP and etoposide. One
hundred mg/m2 of etoposide were infused on days 1, 2, and
3. CDDP was infused at a dose of 80mg/m2 over 2 hours,
with adequate hydration, on day 1. G-CSF was administered
from day 5 until neutrophil recovery. This regimen was
repeated every 4 weeks, and the patient received 6 courses
of the chemotherapy. Toxicity was graded according to the
Common Terminology Criteria for Adverse Events (CTC-
AE), version 3. In the ﬁrst course, both grade 2 anorexia
and grade 1 increase in serum creatinine were observed.
Next, the dose of CDDP was reduced to 64mg/m2.G r a d e
2 anorexia, grade 4 neutropenia, and grade 2 anemia were
observed in all of the courses. After the sixth course, grade 1
neuropathy was observed. The response of the measurable
lesions was assessed by RECIST criteria [7]. CT scans
thereafter revealed a reduction of the hepatic mass in the
posterior inferior segment, from 40mm to 25mm after the
second course, and further to 10mm after the sixth course,
thus indicating a partial response. The hepatic small nodules
also disappeared. The serum levels of NSE and ProGRP
decreased to 1.9ng/mL and 37.3pg/mL, respectively. Next,
the early gastric adenocarcinoma, which did not respond
to the chemotherapy, was completely removed by an endo-
scopic mucosal resection (EMR). The patient was free from
progression of the tumor for 8 months. After regrowth of
the hepatic masses, a biweekly administration of 150mg/m2
of irinotecan was performed. The hepatic mass, however,
increased in size by 27mm and a right pulmonary metastatic
lesion in segment 8 newly appeared after the ﬁfth course
of irinotecan. The serum ProGRP was also increased, up
to 593pg/mL. The administration of amrubicin as a third-
line chemotherapy was then started in August 2006. Forty
mg/m2 of amrubicin were infused on days 1, 2, and 3 every
4 weeks. Grade 1 anorexia, grade 4 neutropenia, and grade 2
anemia were observed in all of the courses. G-CSF had not
been used, because the duration of the grade 4 neutropenia
was only a few days without febrile neutropenia. CT scans
thereafter revealed a reduction of the hepatic mass in the
posterior inferior segment, from 27mm to 15mm after the
second course and further to 9mm after the sixth course,
and the other hepatic and pulmonary nodules were also
reducedinsize,indicatingapartialresponse(Figure 1(c)).In
addition, the serum ProGRP was decreased to 166.1pg/mL.
The administration of amrubicin has been repeated in 8
courses so far. The patient died of progression of cancer
14 months after the initiation of amrubicin monother-
apy, and 26 months after the initiation of the ﬁrst-line
chemotherapy.Case Reports in Medicine 3
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Figure 2: Immunohistochemical examination of small-cell carcinoma of the liver. (a) Tumor cells display large hyperchromatic nuclei and
scanty cytoplasm, H&E. (b) Immunohistochemically, the atypical cells are positive for AE1/AE3, (c) N-CAM and (d) NSE. Magniﬁcation
ratio: 200 times.
3. Discussion
In the literature, there are only 7 cases with a primary small-
cell carcinoma of the liver [8–11]. In these reports, 5 of the 7
patients were treated with a resection or chemotherapy. One
of them survived for 67 months after a right lobectomy [8].
However, 3 of the patients that were treated with a partial
hepatectomy and/or systemic chemotherapy survived for 5,
13, and 15 months, respectively, [9–11].
According to previous reports, the patients with EPSCCs,
especially in the cases of limited-disease treated by local
modalities, have slightly better overall survival than those
with SCLCs [12–14]. Although the pathological mechanism
of the superiority of EPSCCs to SCLCs has not yet been
clariﬁed, several biological features have been reported.
The chromosomal deletion of 3p has been described in
SCLCs, but not in EPSCCs [15]. In addition, while the
overexpression of Bcl-2, an antiapoptotic protein, has been
detected in 75% to 95% of SCLC specimens, only 33% of
gastrointestinal small-cell carcinoma specimens show the
Bcl-2 overexpression [14, 16]. The origins of EPSCCs were
not known well. In this case, it was not clariﬁed whether the
cancer originated from hepatocyte or bile duct cell, because
immunohistochemical examinations revealed that none of
CK-19, CK-20, and hepatocyte speciﬁc marker was positive
as previously reported [11]. Although Zanconati et al.
reportedthatCK-18andCK-19werepositiveintheircases,it
is not clear whether the diﬀerence in immunohistochemical
examinations predicts eﬃcacy of amrubicin [9].
Systemic chemotherapy, however, has been reported to
be equally eﬀective regardless of the location of the primary
site, even though a standard regimen for this disease has
notyetbeenestablished.Thecurrentstandardchemotherapy
for extensive-disease SCLC is a combination of CDDP and
etoposide or irinotecan. The combination of CDDP with
etoposide or irinotecan produced good eﬀects; the response
rates were 68% or 84% and the median survival times (MST)
were 9.4 months or 12.8 months, respectively, [17]. Further-
more, amrubicin, a totally synthetic 9-aminoanthracycline,
has recently emerged as a new candidate agent for the
treatment of SCLCs. Amrubicin is converted to amrubicinol
in human bodies, and amrubicinol mainly inhibits DNA
topoisomerase II [6]. Monotherapy with amrubicin for
refractory or relapsed SCLCs had a response rate of 52%
with an MST of 11.2 months [5]. Combination therapy with
CDDP plus amrubicin for previously untreated SCLSs has
demonstrated a high response rate of 88% and an MST of
13.6 months [18]. In our report, the patient with advanced
small-cell carcinoma of the liver was treated with etoposide,
DNA topoisomerase II inhibitor, and irinotecan, DNA
topoisomerase I inhibitor, previously. He then administered
amrubicin as a third-line chemotherapy. After 2 courses of4 Case Reports in Medicine
monotherapy with amrubicin, the hepatic masses showed
a marked regression, resulting in a partial response. The
patient has been doing well for 14 months since the third-
line chemotherapy was started. This case suggested that
(1) amrubicin was a potent DNA topoisomerase inhibitor
or (2) amrubicin had other mechanisms in the antitumor
avtivity. To our knowledge, this is the ﬁrst case report of
a refractory EPSCC successfully treated with amrubicin.
Although the prognosis of an EPSCC is extremely poor due
to the highly aggressive behavior, eﬀective second- and third-
line treatments are important in improving the prognosis.
Therefore, in light of this, a clinical trial of amrubicin for
EPSCC treatment is warranted.
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